Stay updated on Adolescent Dapagliflozin Safety & Efficacy in T2DM Clinical Trial
Sign up to get notified when there's something new on the Adolescent Dapagliflozin Safety & Efficacy in T2DM Clinical Trial page.

Latest updates to the Adolescent Dapagliflozin Safety & Efficacy in T2DM Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed trial information for a study on dapagliflozin in Type 2 Diabetes patients aged 10-24 years, and the addition of a new EudraCT number and revision number.SummaryDifference25%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check36 days agoNo Change Detected
- Check72 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check94 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Adolescent Dapagliflozin Safety & Efficacy in T2DM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adolescent Dapagliflozin Safety & Efficacy in T2DM Clinical Trial page.